Dorn A, Scovill J P, Ellis W Y, Matile H, Ridley R G, Vennerstrom J L
Pharma Division, Preclinical Research, F. Hoffmann-LaRoche Ltd., Basel, Switzerland.
Am J Trop Med Hyg. 2001 Jul;65(1):19-20. doi: 10.4269/ajtmh.2001.65.19.
Floxacrine was a promising antimalarial compound that led to the identification of WR 243251. On the basis of their structures, we suspected that these compounds might be good inhibitors of hematin polymerization. Indeed, WR 243251 was as potent and floxacrine was only 2-fold less potent than chloroquine as inhibitors of this process. However, this hematin polymerization inhibition did not completely account for the increased antimalarial potency of WR 243251 versus chloroquine. The WR 243251 ketone hydrolysis product WR 243246 was without activity against hematin polymerization. These data also confirm that hematin polymerization inhibition can be quite sensitive to small changes in inhibitor structure.
氟甲喹是一种有前景的抗疟化合物,它促使了WR 243251的发现。基于它们的结构,我们怀疑这些化合物可能是血红素聚合的良好抑制剂。事实上,WR 243251作为该过程的抑制剂效力很强,而氟甲喹的效力仅比氯喹低2倍。然而,这种血红素聚合抑制并不能完全解释WR 243251相对于氯喹抗疟效力增加的原因。WR 243251的酮水解产物WR 243246对血红素聚合没有活性。这些数据也证实了血红素聚合抑制对抑制剂结构的微小变化可能相当敏感。